Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

被引：0
|
作者：
A Ray
D S Das
Y Song
T Hideshima
Y-T Tai
D Chauhan
K C Anderson
机构：
[1] The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center,Department of Medical Oncology
[2] Dana-Farber Cancer Institute,undefined
[3] Harvard Medical School,undefined
来源：
Leukemia | 2018年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：843 / 846
页数：3
相关论文
共 50 条
  • [1] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
    Ray, A.
    Das, D. S.
    Song, Y.
    Hideshima, T.
    Tai, Y-T
    Chauhan, D.
    Anderson, K. C.
    LEUKEMIA, 2018, 32 (03) : 843 - 846
  • [2] Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
    North, Brian J.
    Almeciga-Pinto, Ingrid
    Tamang, David
    Yang, Min
    Jones, Simon S.
    Quayle, Steven N.
    PLOS ONE, 2017, 12 (03):
  • [3] Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
    Ray, Arghya
    Das, Deepika Sharma
    Song, Yan
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2015, 126 (23)
  • [4] Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241
    Bae, Jooeun
    Ho, Matthew
    Nguyen, Brandon
    Ray, Arghya
    Chauhan, Dharminder
    Hideshima, Teru
    Munshi, Nikhil
    Anderson, Kenneth C.
    BLOOD, 2016, 128 (22)
  • [5] Enhanced anti-tumor activity of human placental CD34+derived natural killer cells in combination with ACY-241 for multiple myeloma immunotherapy
    Kang, Lin
    Zhang, Xiaokui
    He, Shuyang
    Voskinarian-Berse, Vanessa
    Stout, Bhavani
    Rousseva, Valentina
    van der Touw, William
    Edinger, James
    Hariri, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
    Kim, Jeong M.
    CANCER RESEARCH, 2015, 75
  • [7] Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma
    Peng, Xiaopeng
    Li, Ling
    Chen, Jingxuan
    Ren, Yichang
    Liu, Jin
    Yu, Ziwen
    Cao, Hao
    Chen, Jianjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (03) : 2434 - 2457
  • [8] Novel anti-CD84 humanized monoclonal antibody enhances anti-tumor immunity in multiple myeloma
    Gunes, Metin
    Lewinsky, Hadas
    Dang, Jessica
    Ma, Ning
    Vaidehi, Nagarajan
    Janakiram, Murali
    Feng, Mingye
    Shachar, Idit
    Rosen, Steven
    Gunes, E. Gulsen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S91 - S91
  • [9] Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity
    Ray, Arghya
    Du, Ting
    Nupponen, Nina N.
    Lehmann, Fredrik
    Lindberg, Jakob
    Gullbo, Joachim
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2021, 138
  • [10] ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)
    Niesvizky, Ruben
    Richardson, Paul G.
    Gabrail, Nashat Y.
    Madan, Sumit
    Yee, Andrew J.
    Quayle, Steven N.
    Almeciga-Pinto, Ingrid
    Jones, Simon S.
    Houston, Lee
    Hayes, Denise
    Van Duzer, John
    Wheeler, Catherine
    Trede, Nikolaus S.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
12345